Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
91.51
Nov 16 • 7:31 AM ET Dollar change+0.19 Percentage change(0.21%)
Index
RUT
Market Cap
5.04B
Enterprise Value
4.83B
Income
196.05M
Sales
1.51B
Book/sh
24.91
Cash/sh
10.23
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
3300
IPO
Feb 11, 1993
P/E
26.28
Forward P/E
19.35
PEG
1.93
P/S
3.35
P/B
3.67
P/C
8.95
P/FCF
39.07
EV/EBITDA
16.42
EV/Sales
3.21
Quick Ratio
1.22
Current Ratio
1.46
Debt/Eq
0.26
LT Debt/Eq
0.25
Option/Short
Yes / Yes
EPS (ttm)
3.48
EPS next Y
4.73
EPS next Q
0.97
EPS this Y
13.71%
EPS next Y
6.66%
EPS next 5Y
10.02%
EPS past 3/5Y
-40.20% 9.06%
Sales past 3/5Y
10.75% 8.24%
EPS Y/Y TTM
189.30%
Sales Y/Y TTM
11.71%
EPS Q/Q
23.11%
Sales Q/Q
9.89%
Insider Own
0.41%
Insider Trans
-6.47%
Inst Own
114.16%
Inst Trans
0.20%
ROA
7.44%
ROE
15.50%
ROIC
11.42%
Gross Margin
68.19%
Oper. Margin
15.14%
Profit Margin
13.01%
SMA20
7.32%
SMA50
13.66%
SMA200
23.15%
Trades
Shs Outstand
55.09M
Shs Float
54.86M
52W High
99.38 -7.92%
52W Low
52.37 74.74%
Volatility
2.52% 3.36%
ATR (14)
3.11
RSI (14)
65.77
Beta
0.90
Rel Volume
0.00
Avg Volume
666.30K
Volume
145
Perf Week
-1.19%
Perf Month
17.96%
Perf Quarter
14.59%
Perf Half Y
26.69%
Perf YTD
48.72%
Perf Year
65.30%
Perf 3Y
93.71%
Perf 5Y
6.39%
Perf 10Y
114.06%
Prev Close
91.32
Price
91.51
Change %
0.21%
Consensus
Buy
Avg. Price Target
$108.10
Implied Upside
+18.1%
Analysts10incl. previous ratings
Rating Distribution7 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 07, 2026Initiated
BCS logoBBarclays
Overweight$105+14.7%
Dec 19, 2025Initiated
KEY logoKKeyBanc Capital Markets
Overweight$81-11.5%
Oct 01, 2025Downgrade
GS logoGGoldman
Buy → Neutral$55-39.9%
May 20, 2025Upgrade
WWolfe Research
Peer Perform → Outperform$60-34.4%
Feb 26, 2025Downgrade
WWolfe Research
Outperform → Peer Perform
Oct 04, 2024Initiated
GS logoGGoldman
Buy$65-29.0%
Sep 17, 2024Upgrade
RRobert W. Baird
Neutral → Outperform$55 → $66-27.9%
Mar 20, 2024Reiterated
NNeedham
Buy
Feb 20, 2024Upgrade
MFG logoMMizuho
Neutral → Buy$60 → $70-23.5%
Sep 06, 2023Initiated
HSBC logoHHSBC Securities
Hold$52-43.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shvartsburg AlexChief Financial OfficerNov 12 '26Sale90.912,500227,27542,147Nov 13 05:01 PM
Shvartsburg AlexOfficerNov 12 '26Proposed Sale90.912,500227,275Nov 12 04:16 PM
Bianchi FrancescoDirectorSep 10 '26Sale78.013,500273,0324,434Sep 14 04:23 PM
Bianchi FrancescoOfficerSep 10 '26Proposed Sale78.013,500273,032Sep 10 04:27 PM
Story BrookeDirectorSep 04 '26Sale81.422,300187,2707,488Sep 08 05:01 PM
Story BrookeOfficerSep 04 '26Proposed Sale81.422,300187,270Sep 04 04:15 PM
Poletti FrancoOfficerSep 02 '26Proposed Sale82.0910,755882,888Sep 02 04:24 PM
Bianchi FrancescoDirectorAug 31 '26Sale79.721,650131,5387,934Sep 02 04:19 PM
Bianchi FrancescoOfficerAug 31 '26Proposed Sale79.721,650131,538Aug 31 04:12 PM
Tezel AhmetChief Innovation OfficerAug 11 '26Option Exercise52.6812,692668,61518,782Aug 13 04:04 PM
Tezel AhmetChief Innovation OfficerAug 11 '26Sale77.742,675207,9426,090Aug 13 04:04 PM
Tezel AhmetOfficerAug 11 '26Proposed Sale78.482,675209,942Aug 11 04:12 PM
WILVER PETER MDirectorJun 15 '26Option Exercise0.004,042010,780Jun 17 04:09 PM
SCHERMERHORN TODD CDirectorJun 15 '26Option Exercise0.004,042013,105Jun 17 04:09 PM
Bianchi FrancescoDirectorJun 15 '26Option Exercise0.004,042011,270Jun 17 04:09 PM
Bianchi FrancescoDirectorJun 15 '26Sale80.191,20096,2289,584Jun 17 04:09 PM
PODLOGAR SUSAN MDirectorJun 15 '26Option Exercise0.004,04206,128Jun 17 04:09 PM
Barry James ChristopherDirectorJun 15 '26Option Exercise0.004,04208,404Jun 17 04:09 PM
Tezel AhmetChief Innovation OfficerJun 15 '26Option Exercise0.002,96507,122Jun 17 04:09 PM
KOZY WILLIAM ADirectorJun 15 '26Option Exercise0.005,681038,248Jun 17 04:09 PM
Enxing Seng StacyDirectorJun 15 '26Option Exercise0.004,042015,793Jun 17 04:08 PM
Story BrookeDirectorJun 15 '26Option Exercise0.004,042010,274Jun 17 04:08 PM
Zurbay DonaldDirectorJun 15 '26Option Exercise0.002,56002,560Jun 17 04:08 PM
Bianchi FrancescoOfficerJun 15 '26Proposed Sale80.191,20096,228Jun 15 04:56 PM
Bianchi FrancescoDirectorMay 26 '26Sale75.751,800136,3507,228May 27 04:51 PM
Bianchi FrancescoOfficerMay 26 '26Proposed Sale75.751,800136,350May 26 04:37 PM
Tezel AhmetChief Innovation OfficerMar 30 '26Option Exercise0.003,40805,343Apr 01 05:20 PM
Poletti FrancoPresident, CardiopulmonaryMar 30 '26Option Exercise0.003,184012,125Apr 01 05:20 PM
Shvartsburg AlexChief Financial OfficerMar 30 '26Option Exercise0.0030,835057,515Apr 01 05:20 PM
Makatsaria VladimirChief Executive OfficerMar 30 '26Option Exercise0.0021,042025,326Apr 01 05:20 PM
Bolton StephaniePresident, Global EpilepsyMar 30 '26Option Exercise0.0017,815030,566Apr 01 05:20 PM
Kozmina NataliaChief Human Resources OfficerMar 30 '26Option Exercise0.006,38906,389Apr 01 05:20 PM
Poletti FrancoPresident, CardiopulmonaryMar 11 '26Option Exercise57.602,140123,26410,990Mar 13 05:25 PM
Poletti FrancoPresident, CardiopulmonaryDec 15 '25Option Exercise0.0096709,266Dec 17 04:06 PM
PODLOGAR SUSAN MDirectorDec 15 '25Option Exercise0.002,35502,355Dec 17 04:06 PM
Hutchinson Michael DamonSVP, CLO and Company SecretaryDec 15 '25Option Exercise0.002,25407,920Dec 17 04:06 PM
Story BrookeDirectorNov 18 '25Sale53.9425013,4856,232Nov 19 03:57 PM
Story BrookeDirectorNov 18 '25Proposed Sale53.9425013,485Nov 18 04:51 PM
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
CEO & DirectorMr. Vladimir A. Makatsaria
Chief Financial OfficerMr. Alex Shvartsburg C.M.A.
Chief Human Resources OfficerMs. Natalia Sergeyevna Kozmina
Chief Innovation OfficerMr. Ahmet Tezel Ph.D.
VP & Chief Accounting OfficerMs. Lindsey Little